EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

东部肿瘤合作组 - 威斯康星州研究

• 批准号: 7257228
• 负责人: JAMES A STEWART
• 金额: $ 58.85万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7257228
• 关键词: Accountability; Acute Myelocytic Leukemia; Address; Adenocarcinoma; Adenovirus p53; Adherence; Adjuvant; Adjuvant Chemotherapy; Adjuvant Therapy; Adverse event; Aesculus hippocastanum; Affect; African American; Alaska Native; Ambulatory Care Facilities; American; American Indian and Alaska Native; American Indians; American Society of Clinical Oncology; Anthracycline Antibiotics; Anthracyclines; Antineoplastic Agents; Applications Grants; Appointment; Area; Arsenic trioxide/Ascorbic acid; Art Therapy; Arteries; Asians; Association of Community Cancer Centers; Award; Axillary lymph node group; B-Lymphocytes; Beds; Behavior; Berlin; Bibliography; Bilateral; Biliary; Biological Response Modifier Therapy; Blast Phase; Blood; Blood Vessels; Blood specimen; Bone Density; Bone Marrow Transplantation; Brain; Brain Neoplasms; Breast; Bronchoalveolar Lavage; Calendar; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Model; Cancer Patient; Cancer Survivor; Cancer Therapy Evaluation Program; Candidate Disease Gene; Caracemide; Carboplatin; Carboplatin/Paclitaxel; Carboplatin/Paclitaxel/Thalidomide; Carboxyamidotriazole; Carcinoma; Caring; Carmustine; Categories; Cells; Center Core Grants; Cervix Uteri; Cessation of life; Chemoprevention; Chemotherapy-Oncologic Procedure; Chest; Chronic; Chronic Lymphocytic Leukemia; Cisplatin; Cisplatin/Paclitaxel; Cities; Cladribine; Clinic; Clinical; Clinical Nursing; Clinical Pharmacology; Clinical Research; Clinical Research Associate; Clinical Treatment; Clinical Trials; Clinics and Hospitals; Coffee; Collaborations; Colon; Colon Carcinoma; Colorectal; Colorectal Cancer; Commit; Committee Members; Communication; Communities; Community Clinical Oncology Program; Community Health Centers; Companions; Complex; Comprehensive Cancer Center; Count; Country; County; Critiques; Cyclophosphamide; Cyclophosphamide/Doxorubicin/Interferon Alfa/Prednisone/Vincristine; DL-alpha-Difluoromethylornithine; Dacarbazine; Daily; Data; Data Collection; Data Quality; Databases; Depth; Development; Developmental Therapeutics Program; Diagnostic; Diffuse; Diffuse Large-Cell Lymphoma; Discipline of Nursing; Disease; Disease remission; Docetaxel/Gemcitabine; Doctor of Pharmacy; Doctor of Philosophy; Documentation; Dose; Double-Blind Method; Doxorubicin; Drops; Eastern Cooperative Oncology Group; Echinomycin; Economics; Education; Educational Curriculum; Educational workshop; Elderly; Enrollment; Ensure; Epidermal Growth Factor Receptor; Epithelial; Esophageal; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Esophagus; Estramustine; Ethnic Origin; Ethnicity not Reported; Etoposide; Evaluation; Evaluation Studies; Excision; Expressed Sequence Tags; Extensive Stage; Faculty; Family; Fatigue; Fellowship; Fellowship Program; Female; Financial compensation; Floxuridine; Fludarabine/Rituximab; Fluorouracil; Fluorouracil/Levamisole; Flutamide; Follicular Lymphoma; Fostering; Foundations; Foxes; Funding; Future; Gefitinib; Gender; Gene Therapy Agent; Genes; Genetic Variation; Genets; Genotype; Genus Cola; Germ cell tumor; Glioblastoma; Glioma; Goals; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Gray unit of radiation dose; Group Meetings; Group Structure; Growth; Gynecologic; Head; Head and Neck Cancer; Head and neck structure; Health; Health Insurance Portability and Accountability Act; Health behavior; Health care facility; Health system; Heart Diseases; Hematology; Hematopathology; Hepatic; Hispanics; Histopathologic Grade; Hormones; Hospital safety; Hospitals; Hour; Housing; Human; Hypermethylation; Illinois; Image; Immunotherapy; Incidence; Incidence Study; Individual; Indolent; Industry; Information Dissemination; Infusion procedures; Inpatients; Institution; Interferon Alfa-2a; Interferon Alfa-2b; Interferon-alpha; Interferon-beta; Interferons; Interleukin-1; Interleukin-2; Internal Medicine; Internet; Intra-abdominal; Investments; Iowa; Irrigation; Islet Cell; Islets of Langerhans; Isotretinoin; Joints; Jordan; Journals; Kidney; Kidney Failure; Laboratories; Laboratory Research; Large Intestine Carcinoma; Lead; Leadership; Learning; Left; Length; Leucovorin; Linear Accelerator Radiotherapy Systems; Location; Lomustine; Lung; Lung diseases; Lymph node excision; Lymphedema; Lymphoma; MGMT gene; Maintenance; Maintenance Therapy; Malignant Epithelial Cell; Malignant Neoplasms; Malignant lymphoid neoplasm; Malignant neoplasm of esophagus; Malignant neoplasm of large intestine; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Mantle Cell Lymphoma; Manuscripts; Maps; Measures; Medical; Medical Oncologist; Medical Oncology; Medical center; Medicine; Melphalan; Menogaril; Mentors; Meta-Analysis; Metastatic Melanoma; Metastatic Neoplasm to the Liver; Metastatic Prostate Cancer; Methotrexate; Methylphenidate; Michigan; Minority; Minority Groups; Mitosis; Modality; Monitor; Morphology; Mucositis; Multiple Myeloma; Murine Monoclonal Antibody 2B8; Mutation; Myelogenous; N phosphonoacetyl L aspartate; N(delta)-acetylornithine, -isomer; N-dodecanoylglutamic acid, -isomer, sodium salt; N-methylformamide; NCI Center for Cancer Research; NCI-Designated Cancer Center; Names; National Surgical Adjuvant Breast and Bowel Project; Native Hawaiian or Other Pacific Islander; Neck; Negative Axillary Lymph Node; Neoplasm Metastasis; New Agents; Newly Diagnosed; Non-Hodgkin' s Lymphoma; Non-Measurable; Non-Small-Cell Lung Carcinoma; None or Not Applicable; Not Hispanic or Latino; Notification; Numbers; Nurses; Nursing Research; Oncologist; Oncology Group; Ontology; Operative Surgical Procedures; Oral; Orchiectomy; Outcome; Outpatients; Ovarian; Ovary; Paclitaxel; Pain; Palliative Care; Palliative Medicine; Palliative Surgery; Palmar-plantar erythrodysesthesia syndrome; Pancreas; Pancreatic carcinoma; Paper; Parkinson Disease; Participant; Pathologic; Pathology; Pathology, Other; Patient Care Team; Patients; Pelvis; Performance; Personal Satisfaction; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Pharmacy facility; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Phase III Clinical Trials; Physicians; Pilot Projects; Planet Mars; Play; Policies; Policy Research; Population; Positioning Attribute; Positive Lymph Node; Postmenopause; Postoperative Period; Poxviridae; Predisposition; Preparation; Prevention; Prevention Research; Principal Investigator; Problem Solving; Procarbazine; Procedures; Process; Productivity; Prognostic Factor; Program Development; Prospective Studies; Prostate; Prostate Cancer Prevention Trial; Prostate carcinoma; Prostatic Intraepithelial Neoplasias; Protocols documentation; Published Comment; Publishing; Purpose; Pycnogenol; Quality of life; Quality-of-Life Assessment; Race; Radiation; Radiation Oncology; Radiation Therapy Oncology Group; Radiation therapy; Radical Prostatectomy; Radiology Specialty; Radiosurgery; Radium; Randomized; Randomized Controlled Clinical Trials; Range; Rate; Recording of previous events; Recurrence; Refractory; Regulation; Relapse; Renal Cell Carcinoma; Reporting; Research; Research Activity; Research Ethics Committees; Research Infrastructure; Research Personnel; Research Support; Resected; Residual state; Resistance; Resources; Retirement; Retrieval; Review Committee; Review Literature; Risk; Risk Factors; Robin bird; Role; Ruta; S Phase; SDZ-PSC-833; SECTM1 gene; Safety; Salvage Therapy; Sampling; Schedule; Science; Scientist; Screening procedure; Seeds; Selenium; Semustine; Services; Siblings; Side; Signal Transduction; Site; Site Visit; Social Security Number; Societies; Southwest Oncology Group; Specific qualifier value; Staging; Standards of Weights and Measures; Stomach; Stomach Carcinoma; Strategic Planning; Stratification; Streptozocin; Structure; Sulindac Sulfone; Supratentorial; Surgeon; Suspension substance; Suspensions; Symptoms; System; TP53 gene; Telephone; Testing; Text; Thalidomide; Therapeutic; Therapeutic Studies; Therapeutics Committee; Therapy Clinical Trials; Thoracic Oncology; Time; Title; Today; Topotecan; Toxic effect; Training; Training Programs; Transitional Cell Carcinoma; Translating; Transplantation; Travel; Treatment Protocols; Tretinoin; Trimetrexate; Tumor Burden; Tumor Debulking; United States Food and Drug Administration; United States National Institutes of Health; Universities; University Hospitals; University of Wisconsin Comprehensive Cancer Center; Update; Upper arm; Urology; Urothelium; VA-2; Vaccination; Vaccines; Veterans; Vincristine; Vinorelbine; Visit; Wages; West Virginia; Wisconsin; Wolves; Woman; Wood material; Work; Y 90 Ibritumomab Tiuxetan; Zoledronate; abstracting; alpha-difluoromethyl-DOPA, -isomer; alpha-methylornithine dihydrochloride, -isomer; anticancer research; authority; base; cancer care; cancer cell; cancer research center director; cancer therapy; cancer type; capecitabine; case finding; celecoxib; chemotherapy; cisplatin/etoposide protocol; citrin; clinically relevant; college; computerized; concept; cost; cyclophosphamide/doxorubicin/lomustine protocol; data management; day; design; docetaxel; driving force; drug development; experience; falls; flu; follow-up; gastrointestinal; gemcitabine; gene therapy; homoharringtonine; hormone therapy; human prostaglandin D2 receptor; human subject; ilium; improved; innovation; instructor; interdisciplinary approach; interest; iodonitrotetrazolium; irradiation; leukemia; lung Carcinoma; lung small cell carcinoma; male; malignant breast neoplasm; medical schools; melanoma; member; men; multidisciplinary; neuropsychiatry; novel; novel strategies; older patient; oligodendroglioma; oncology; outreach program; patient safety; performance status 2; perilla alcohol; pilot trial; piritrexim; posters; preference; probation; professor; prognostic; programs; prospective; protocol development; quality assurance; repository; research study; response; rituximab; sex; skills; success; symposium; symptom management; therapy development; tool; trafficking; trial comparing; tumor; urinary; urologic

DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the University of Wisconsin Comprehensive Cancer Center (UWCCC) and affiliated institutions. The clinical programs of the UWCCC are designed to improve both the treatment and care of cancer patients as well as to reduce the burden of the cancer problem in general. Our long association with the Eastern Cooperative Oncology Group (ECOG) has been beneficial in enhancing these goals. UWCCC Investigators have a history of strong commitment to ECOG accrual as well as administrative and scientific leadership. UWCCC clinics are organized along disease specific lines with efforts to enhance the multidisciplinary approaches needed for today's optimal cancer care and clinical research. During the last grant cycle this approach has been strengthened with recruitment in Medical Oncology and Surgery, new clinic space and enhancement of computerized research database facilities. All of this has improved our ECOG effort as manifested by consistent high accrual and group leadership activities. UW investigators chair the GU and Thoracic committees and co-chair the Pharmacology committee. UW investigators will lead chemoprevention efforts in ECOG. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative and scientific leadership. UW ECOG affiliates continue to contribute with significant accrual and high quality data management and rank among the best in ECOG. ECOG studies and a clinical trials approach in cancer care are essential for continued high quality in the cancer programs at UW and throughout the region. ECOG studies serve as a core curriculum for trainees in Hematology and Medical and Radiation Oncology and as a basis for clinical strategies. The ECOG program remains an important component of the UWCCC cancer research effort and UWCCC contributions to ECOG remain equally important to the Group.

描述（由申请人提供）：本申请为威斯康星大学综合癌症中心（UWCCC）及其附属机构的东部肿瘤合作小组（ECOG）的活动寻求支持。UWCCC的临床项目旨在改善癌症患者的治疗和护理，并减轻癌症问题的负担。我们与东部肿瘤合作组织（ECOG）的长期合作有助于实现这些目标。